216 related articles for article (PubMed ID: 16969258)
1. Evaluation of transcriptional activity of the oestrogen receptor with sodium iodide symporter as an imaging reporter gene.
Kang JH; Chung JK; Lee YJ; Kim KI; Jeong JM; Lee DS; Lee MC
Nucl Med Commun; 2006 Oct; 27(10):773-7. PubMed ID: 16969258
[TBL] [Abstract][Full Text] [Related]
2. Enhanced expression of adenovirus-mediated sodium iodide symporter gene in MCF-7 breast cancer cells with retinoic acid treatment.
Lim SJ; Paeng JC; Kim SJ; Kim SY; Lee H; Moon DH
J Nucl Med; 2007 Mar; 48(3):398-404. PubMed ID: 17332617
[TBL] [Abstract][Full Text] [Related]
3. Transcriptional activation of the oxytocin promoter by oestrogens uses a novel non-classical mechanism of oestrogen receptor action.
Koohi MK; Ivell R; Walther N
J Neuroendocrinol; 2005 Apr; 17(4):197-207. PubMed ID: 15842231
[TBL] [Abstract][Full Text] [Related]
4. Activator protein-2gamma (AP-2gamma) expression is specifically induced by oestrogens through binding of the oestrogen receptor to a canonical element within the 5'-untranslated region.
Orso F; Cottone E; Hasleton MD; Ibbitt JC; Sismondi P; Hurst HC; De Bortoli M
Biochem J; 2004 Jan; 377(Pt 2):429-38. PubMed ID: 14565844
[TBL] [Abstract][Full Text] [Related]
5. Stimulation of retinoic acid-induced functional sodium iodide symporter (NIS) expression and cytotoxicity of ¹³¹I by carbamazepine in breast cancer cells.
Willhauck MJ; O Kane DJ; Wunderlich N; Göke B; Spitzweg C
Breast Cancer Res Treat; 2011 Jan; 125(2):377-86. PubMed ID: 20300827
[TBL] [Abstract][Full Text] [Related]
6. Comparative study of oestrogenic properties of eight phytoestrogens in MCF7 human breast cancer cells.
Matsumura A; Ghosh A; Pope GS; Darbre PD
J Steroid Biochem Mol Biol; 2005 Apr; 94(5):431-43. PubMed ID: 15876408
[TBL] [Abstract][Full Text] [Related]
7. Probasin promoter (ARR(2)PB)-driven, prostate-specific expression of the human sodium iodide symporter (h-NIS) for targeted radioiodine therapy of prostate cancer.
Kakinuma H; Bergert ER; Spitzweg C; Cheville JC; Lieber MM; Morris JC
Cancer Res; 2003 Nov; 63(22):7840-4. PubMed ID: 14633711
[TBL] [Abstract][Full Text] [Related]
8. In vivo radioiodide imaging and treatment of breast cancer xenografts after MUC1-driven expression of the sodium iodide symporter.
Dwyer RM; Bergert ER; O'connor MK; Gendler SJ; Morris JC
Clin Cancer Res; 2005 Feb; 11(4):1483-9. PubMed ID: 15746050
[TBL] [Abstract][Full Text] [Related]
9. [Establishment of drug screening model based on transcriptional regulation of estrogen responsive element].
Wang LQ; Lu QJ; Niu JZ; Wang JF; Qu YY; Wen LQ; Zheng LT; Chen YY; Zhang M
Zhongguo Zhong Yao Za Zhi; 2003 Jun; 28(6):536-40. PubMed ID: 15015335
[TBL] [Abstract][Full Text] [Related]
10. The pan-DAC inhibitor LBH589 is a multi-functional agent in breast cancer cells: cytotoxic drug and inducer of sodium-iodide symporter (NIS).
Fortunati N; Catalano MG; Marano F; Mugoni V; Pugliese M; Bosco O; Mainini F; Boccuzzi G
Breast Cancer Res Treat; 2010 Dec; 124(3):667-75. PubMed ID: 20213084
[TBL] [Abstract][Full Text] [Related]
11. Enhanced formation of non-phenolic androgen metabolites with intrinsic oestrogen-like gene transactivation potency in human breast cancer cells: a distinctive metabolic pattern.
Pérez-Palacios G; Santillán R; García-Becerra R; Borja-Cacho E; Larrea F; Damián-Matsumura P; González L; Lemus AE
J Endocrinol; 2006 Sep; 190(3):805-18. PubMed ID: 17003281
[TBL] [Abstract][Full Text] [Related]
12. Establishment and characterization of a breast cancer cell line expressing Na+/I- symporters for radioiodide concentrator gene therapy.
Nakamoto Y; Saga T; Misaki T; Kobayashi H; Sato N; Ishimori T; Kosugi S; Sakahara H; Konishi J
J Nucl Med; 2000 Nov; 41(11):1898-904. PubMed ID: 11079502
[TBL] [Abstract][Full Text] [Related]
13. Oestrogenic activity of benzyl salicylate, benzyl benzoate and butylphenylmethylpropional (Lilial) in MCF7 human breast cancer cells in vitro.
Charles AK; Darbre PD
J Appl Toxicol; 2009 Jul; 29(5):422-34. PubMed ID: 19338011
[TBL] [Abstract][Full Text] [Related]
14. AFP promoter enhancer increased specific expression of the human sodium iodide symporter (hNIS) for targeted radioiodine therapy of hepatocellular carcinoma.
Ma XJ; Huang R; Kuang AR
Cancer Invest; 2009 Jul; 27(6):673-81. PubMed ID: 19241193
[TBL] [Abstract][Full Text] [Related]
15. Reduction of stimulated sodium iodide symporter expression by estrogen receptor ligands in breast cancer cells.
Cheong SJ; Jang D; Jeong HJ; Lim ST; Sohn MH; Katzenellenbogen JA; Kim DW
Nucl Med Biol; 2011 Feb; 38(2):287-94. PubMed ID: 21315285
[TBL] [Abstract][Full Text] [Related]
16. Mitogen-activated protein kinase signaling enhances sodium iodide symporter function and efficacy of radioiodide therapy in nonthyroidal cancer cells.
Jung KH; Paik JY; Ko BH; Lee KH
J Nucl Med; 2008 Dec; 49(12):1966-72. PubMed ID: 18997042
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of sodium/iodide symporter expression in thyroid and breast cancer.
Kogai T; Taki K; Brent GA
Endocr Relat Cancer; 2006 Sep; 13(3):797-826. PubMed ID: 16954431
[TBL] [Abstract][Full Text] [Related]
18. Effect of all-trans retinoic acid on sodium/iodide symporter expression, radioiodine uptake and gene expression profiles in a human anaplastic thyroid carcinoma cell line.
Jeong H; Kim YR; Kim KN; Choe JG; Chung JK; Kim MK
Nucl Med Biol; 2006 Oct; 33(7):875-82. PubMed ID: 17045167
[TBL] [Abstract][Full Text] [Related]
19. Potential use of an estrogen-glucocorticoid receptor chimera as a drug screen for tissue selective estrogenic activity.
Maru BS; Tobias JH; Rivers C; Caunt CJ; Norman MR; McArdle CA
Bone; 2009 Jan; 44(1):102-12. PubMed ID: 18976723
[TBL] [Abstract][Full Text] [Related]
20. Alpha-fetoprotein promoter-targeted sodium iodide symporter gene therapy of hepatocellular carcinoma.
Willhauck MJ; Sharif Samani BR; Klutz K; Cengic N; Wolf I; Mohr L; Geissler M; Senekowitsch-Schmidtke R; Göke B; Morris JC; Spitzweg C
Gene Ther; 2008 Feb; 15(3):214-23. PubMed ID: 17989705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
